Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic …
M Perera, N Papa, D Christidis, D Wetherell… - European urology, 2016 - Elsevier
Context Positron emission tomography (PET) of 68 Ga-labelled prostate-specific membrane
antigen (68 Ga-PSMA) is an emerging imaging modality introduced to assess the burden of …
antigen (68 Ga-PSMA) is an emerging imaging modality introduced to assess the burden of …
Current use of PSMA–PET in prostate cancer management
T Maurer, M Eiber, M Schwaiger… - Nature Reviews …, 2016 - nature.com
Currently, the findings of imaging procedures used for detection or staging of prostate
cancer depend on morphology of lymph nodes or bone metabolism and do not always meet …
cancer depend on morphology of lymph nodes or bone metabolism and do not always meet …
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
Purpose: Current FDA-approved imaging modalities are inadequate for localizing prostate
cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule …
cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule …
Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial
WP Fendler, J Calais, M Eiber, RR Flavell… - JAMA …, 2019 - jamanetwork.com
Importance In retrospective studies, 68 Ga-PSMA-11 positron emission tomographic (PET)
imaging improves detection of biochemically recurrent prostate cancer compared with …
imaging improves detection of biochemically recurrent prostate cancer compared with …
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm …
Summary Background National Comprehensive Cancer Network guidelines consider 18 F-
fluciclovine PET-CT for prostate cancer biochemical recurrence localisation after radical …
fluciclovine PET-CT for prostate cancer biochemical recurrence localisation after radical …
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
WP Fendler, M Eiber, M Beheshti, J Bomanji… - European journal of …, 2017 - Springer
The aim of this guideline is to provide standards for the recommendation, performance,
interpretation and reporting of 68 Ga-PSMA PET/CT for prostate cancer imaging. These …
interpretation and reporting of 68 Ga-PSMA PET/CT for prostate cancer imaging. These …
Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT
M Eiber, K Herrmann, J Calais… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA)–ligand PET imaging provides unprecedented
accuracy for whole-body staging of prostate cancer. As PSMA-ligand PET/CT is increasingly …
accuracy for whole-body staging of prostate cancer. As PSMA-ligand PET/CT is increasingly …
Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with …
J Violet, P Jackson, J Ferdinandus… - Journal of Nuclear …, 2019 - Soc Nuclear Med
177Lu-prostate-specific membrane antigen (PSMA)–617 enables targeted delivery of β-
particle radiation to prostate cancer. We determined its radiation dosimetry and relationships …
particle radiation to prostate cancer. We determined its radiation dosimetry and relationships …
German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients
K Rahbar, H Ahmadzadehfar… - Journal of Nuclear …, 2017 - Soc Nuclear Med
177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy
(RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by …
(RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by …
225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer
C Kratochwil, F Bruchertseifer, FL Giesel… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer.
Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA …
Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA …